A Safety and Efficacy Study of Hymecromone Tablets for the Treatment of Patients With COVID-19.
Status:
Recruiting
Trial end date:
2022-11-15
Target enrollment:
Participant gender:
Summary
The coronavirus (SARS-CoV-2) is a new strain of coronavirus found in human in 2019, which
causes epidemic worldwide. A study found that the increase in hyaluronic acid levels is
closely related to the clinical symptoms of COVID-19, including pulmonary ground glass
lesions, lymphocytopenia, immune response and cytokine storms, systemic vascular diseases,
thrombotic coagulation disorders, which suggests that hyaluronic acid could be an important
target for COVID-19 treatment and could improve the clinical symptoms of COVID-19 patients.
The results from a recent clinical trial recruited 144 patients with COVID-19 show that the
inhibitor of hyaluronic acid synthesis, hymecromone, can significantly improve clinical
symptoms, such as lung lesions and lymphocytopenia in COVID-19 patients. Therefore,
hymecromone has the potential to become one of the options of COVID-19 treatment.
This study is a single-center, randomized, parallel controlled, double-blind clinical trial
designed to evaluate the efficacy and safety of Hymecromone tablets in subjects aged 18-90
years (with boundary values) with a confirmed mild or moderate form of COVID-19 infection.
The aim of this study is to optimize the program of the combination of hymecromone in the
treatment of COVID-19 to improve the therapeutic effect.